דר איתן פאר מצגת גלולות

  • Published on
    12-Aug-2015

  • View
    2.849

  • Download
    2

Embed Size (px)

Transcript

<ul><li><p> ' "</p></li><li><p>" </p><p>" </p></li><li><p> 15-35 ' -</p><p> ' - :- GNRH CILIA </p><p> " </p><p>" </p></li><li><p>" </p><p>" </p></li><li><p>" </p><p>" </p></li><li><p> - FSH .. 15" - . - (30 ") ( ) ." </p><p>" </p></li><li><p> , 17 , 2E :- - , , - ligand DNA RNA DNA . , , -- messengers NO, , kinase .- NO ." </p><p>" </p></li><li><p>Pathways for Estrogen Carcinogenesis" </p><p>" </p></li><li><p> , , , . ' C.O.M.T . , , ' . - tissue estrogen levels . - ." </p><p>" </p></li><li><p>" </p><p>" </p></li><li><p>" </p><p>" </p></li><li><p> ?" </p><p>" </p></li><li><p>2030" </p><p>" </p></li><li><p> 30 ' 20 , , . - Pearl Index- -100 , ( 1200 ).Archer 1708 (26,554 ) 20 ' E 1143 30:-PI- 20 0.88PI- 30 1.02- Rosenberg M.J- Contraception- 1999:60:321-329Archer D- Am J Obstet Gynecol- 1999;185- 39-44</p><p>" </p><p>" </p></li><li><p> 30 20- , 6676 (R.R-1.6) - (R.R=1.3). . .Rosenberg M.J- Contraception- 1995;51:283-288Akerlund M Br J Obstet Gynecol- 1993;100:832-838Appel T.B- Contraception -1987;35:523-532Endrikat J- Contraception 1997;55:131-137" </p><p>" </p></li><li><p> - 30 20Meade 50 30 ' E 60% VTE 20 'Young , , Meade T.B Br Med J 1980;280:1157-1161Young R.L Am J Obstet Gynecol 1999;181:59-62" </p><p>" </p></li><li><p> - , 4 . , Rosenberg M J- Contraception , 1995;52:137-141" </p><p>" </p></li><li><p> . , . , , , . , , , .3 , , ." </p><p>" </p></li><li><p>" </p><p>" </p></li><li><p>" </p><p>" </p></li><li><p> - , , ' ( AKR1C4) . ( LEU VAL). 68% . . . ." </p><p>" </p></li><li><p>GESTODENE ( ). 100%, . . .Wilde MI, Balfour JA, Drugs:1995 Aug:50(2) 364-95" </p><p>" </p></li><li><p>" </p><p>" </p></li><li><p> , , . , .Endrikat J-Contraception 199;60:269-274Crook D Am J Obstet Gynecol- 1993;69:1183-1189Rosenberg MJ Contraception 1996;53:85-9</p><p>" </p><p>" </p></li><li><p> -HDL LDL '- !!- HDL LDL" </p><p>" </p></li><li><p> .. , LDL, ., , , NO . . SHBG" </p><p>" </p></li><li><p> " </p><p>" </p></li><li><p> 70-80%- . - 50% . . , . .</p><p>" </p><p>" </p></li><li><p> " </p><p>" </p></li><li><p>HYSTEROSCOPIC VIEW OF ATROPHIC ENDOMETRIAL CAVITYCourtesy of Panay N" </p><p>" </p></li><li><p>WHY BREAKTHROUGH BLEEDING?Dilated surface vessels in a Norplant user with bleeding on minimal pressureHickey M et al. Hum Reprod 1998;13(11):31903196" </p><p>" </p></li><li><p>" </p><p>" </p></li><li><p> " </p><p>" </p></li><li><p> - - 20 '" </p><p>" </p></li><li><p> 8058 . 77 70% - .18% - ( ). , .</p><p>" </p><p>" </p></li><li><p>" </p><p>" </p></li><li><p>Non Contraceptive Benefits of OCMenorrhgia Irregular mensesEndometrial CADysmenorrheaIron Def. AnemiaAcneHirsutism Ovarian CAFunctional Ov. CystsBenign Breast DisPMSOsteoporosisSalpingitisSherifk K Am J Obstet Gynecol- 1999 ;80- s343-348Thorneycroft I.H- Contraception- 1999;60:255-263" </p><p>" </p></li><li><p> 18% &gt; 5 . HRT" </p><p>" </p></li><li><p> ( , ). B12 - </p><p> - B12 , ." </p><p>" </p></li><li><p> . corneal curvature ." </p><p>" </p></li><li><p>VTE - - 10&lt; - X 4 45&lt; VTE BMI 35&lt; " </p><p>" </p></li><li><p>" </p><p>" </p></li><li><p>" </p><p>" </p></li><li><p>" </p><p>" </p></li><li><p>" </p><p>" </p></li><li><p>" </p><p>" </p></li><li><p>" </p><p>" </p></li><li><p>" </p><p>" </p></li><li><p>" </p><p>" </p></li><li><p>LEPTIN , 167-AA, . , , . ( ) Neuropeptide Y . ( ). .</p><p>" </p><p>" </p></li><li><p>.. E . FSH, GNRH LH . , , , , . = !!- - !!" </p><p>" </p></li><li><p>, , , , . .2 , , . ." </p><p>" </p></li><li><p> - PMS/PMDD .:- , - </p><p> , , , - ( ) " </p><p>" </p></li><li><p>PMS/PMDD . / , . , , , ... , , '." </p><p>" </p></li><li><p>" </p><p> ?</p><p>" </p><p>***********Hysteroscopic view of endometrial cavity of women taking Norplant (levonorgestrel-releasing contraceptive hormone). ****</p></li></ul>